Your browser doesn't support javascript.
loading
A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
Zhang, Qingyuan; Tao, Rong; Li, Zhenyu; Guo, Haiyi; Ji, Meng; Zhang, Lu; Huang, Jane; Lina, Fu; Zhong, Jinhua; Zhou, Jianfeng.
Afiliação
  • Zhang Q; Department of Internal Medicine-Oncology, Cancer Hospital of Harbin Medical University, Harbin, China.
  • Tao R; Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Li Z; The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Guo H; BeiGene (Shanghai) Co., Ltd, Shanghai, China.
  • Ji M; BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Zhang L; BeiGene (Shanghai) Co., Ltd, Shanghai, China.
  • Huang J; BeiGene USA, Inc, San Mateo, CA, USA.
  • Lina F; BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Zhong J; BeiGene (Shanghai) Co., Ltd, Shanghai, China.
  • Zhou J; Tongji Hospital, Tongji Medical College, Wuhan, China.
Leuk Lymphoma ; 63(10): 2503-2506, 2022 10.
Article em En | MEDLINE | ID: mdl-35855547
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article